A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in K

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

Open

Protocol code: 299AR301
EudraCT code: No aplica
Research group: Nephrology and kidney transplantation
Service: Nephrology
Principal investigator: Bestard Matamoros, Oriol
Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Phase: Fase III